Yet Another Sustained-Delivery Anti-VEGF Drug Ready For Phase 2

A report at the Hawaiian Eye & Retina 2019 conference revealed another sustained-delivery drug, GB-102, for treatment of wet age-related macular degeneration (AMD).  Graybug Vision’s ADAGIO study has now provided evidence that GB-102 can continuously inhibit activity of VEGF for several months. The treatment was well-tolerated in the study and found to be free of dose [Read More]

NIH researchers prevent blindness in animal models of dry AMD

Findings set stage for first clinical trial of stem cell-based therapeutic approach for AMD. Using a novel patient-specific stem cell-based therapy, researchers at the National Eye Institute (NEI) prevented blindness in animal models of geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD). The protocols established by the animal study* set the stage [Read More]

KSI-301 Joins List of Proposed Longer Lasting Anti-VEGF Drugs

Kodiak Sciences Inc. has announced promising results from their Phase 1 clinical trial of KSI-301, a novel anti-VEGF compound for the treatment of age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Currently approved anti-VEGF drugs require several monthly “loading dosages” at the beginning of the treatment regimen. Twelve weeks after a single dose [Read More]

Self-Monitoring For Neovascularization Can Save Vision

Neovascularization is the term applied to growth of errant blood vessels into the retina. This can occur whenever the retina is compromised by diseases such as age-related macular degeneration, myopic degeneration, or diabetic macular edema. Neovascularization is initially identified during dilated eye examinations, the scheduling of which depends upon the patient’s initiative in acquiring and [Read More]